Cosmos Health Inc. Stock Price, News & Analysis

Cosmos Holdings (NASDAQ:COSM) announced a binding letter of intent to acquire Pharmaceutical Laboratories CANA S.A., a Greek pharmaceutical company. Founded in 1928, Cana is known for its manufacturing and distribution of diverse health products and has partnerships with major global companies such as AstraZeneca and Merck. This acquisition aims to enhance Cosmos's vertical integration and expand its product portfolio. The move is expected to strengthen its competitive position in the pharmaceutical market, leveraging Cana's established customer base and operational capabilities.

Cosmos Holdings (Nasdaq:COSM) announced its subsidiary, Decahedron Ltd., has gained full membership in the PAGB, a leading UK consumer healthcare association. This membership enhances visibility for Sky Premium Life products on PAGB's OTC Directory, which attracts over 50,000 views monthly from healthcare professionals. The partnership is expected to improve access for pharmacies and boost consumer confidence in the products, which are now recognized as regulated items. This strategic move aims to expand Cosmos's market reach within the European Economic Area.

Cosmos Holdings (Nasdaq:COSM) announced the addition of Dr. Panagiotis Zoumpoulakis to its Advisory Board. With over 20 years in research, particularly in nutraceuticals, Dr. Zoumpoulakis holds a Ph.D. and an MBA. He is currently an Associate Professor at the University of West Attica and has published over 130 scientific works. His appointment comes after a strategic partnership with Cloudpharm P.C. to explore microbiome-based treatments for obesity. CEO Greg Siokas expressed confidence that Dr. Zoumpoulakis' expertise will be crucial for future projects.

Cosmos Holdings (Nasdaq:COSM) has announced an agreement to acquire LIFE NLB Ltd.'s product portfolio, which includes Bone-Vio® and Bone-X, aimed at enhancing bone health by targeting the gastrointestinal microbiome. This acquisition is positioned to establish Cosmos in the expanding osteoporosis drug market, valued at USD 13.36 billion and projected to grow at a CAGR of 6.83% to USD 20.17 billion by 2026. The Bone-Vio® product's clinical trial results are expected in 2023, highlighting its potential effectiveness in addressing osteoporosis.

Cosmos Holdings (NASDAQ:COSM) has formed a strategic partnership with Cloudpharm P.C., focused on developing innovative products targeting the human gastrointestinal microbiome. This collaboration aims to manage obesity by combining computational tools and natural products, with clinical trials expected to conclude in late 2023. The global weight management market, valued at USD $132.7 billion in 2021, is projected to grow at a CAGR of 9.7% over the next nine years. The partnership seeks to create high-quality nutraceuticals to address obesity and related health issues.

Cosmos Holdings (NASDAQ: COSM) announces the commercial launch of its Sky Premium Life nutraceutical products on Amazon in the U.S., following successful market entries in Canada, the U.K., and Singapore. The company plans to introduce 15 SKUs in the third quarter of 2022 and aims for all 85 SKUs available by year-end. The U.S. nutraceutical market is projected to grow at a 7.1% CAGR, reaching $138.0 billion by 2027, driven by health-conscious consumer trends. CEO Greg Siokas emphasizes the significant demand for high-quality supplements.

Cosmos Holdings (NASDAQ: COSM) reported strong financial results for Q1 2022, with revenue increasing by 12.5% to $13.1 million and gross profit soaring 88.9% to $1.89 million. The company achieved a net income of $0.2 million and EBITDA of $1.2 million. Growth was driven by a 49.2% increase in sales of its proprietary nutritional supplements. Operating expenses were reduced by nearly 40%, enhancing profitability. The company aims to expand its nutraceutical portfolio and geographic reach, launching products in Amazon Singapore and Canada.

Cosmos Holdings (Nasdaq: COSM) announced the launch of its Sky Premium Life nutraceutical products on Amazon Canada. This initiative, facilitated by its subsidiary, SkyPharm S.A., will introduce 22 stock-keeping units (SKUs) in Q2 2022, aiming for a total of 85 SKUs by year-end. The North American nutraceutical market, valued at $88.3 billion in 2021, is expected to reach $118.73 billion by 2026, driven by heightened health awareness and demand for supplements during the COVID-19 pandemic.

Cosmos Holdings (NASDAQ:COSM) announced the appointment of Dr. Anastasios Aslidis to its Board of Directors and audit committee. Dr. Aslidis, a finance expert with over 30 years in the maritime industry, currently serves as CFO for EuroDry and Euroseas. His extensive experience in corporate finance is expected to aid Cosmos in scaling its operations and expanding its international presence. CEO Greg Siokas expressed confidence in Dr. Aslidis's background, emphasizing its alignment with the company's growth strategy in the nutraceutical and pharmaceutical markets.